Avastin helps fight macular degeneration: study
– Sun May 8, 7:37 am ET WASHINGTON (AFP) – The anti-cancer drug Avastin is as effective in fighting macular degeneration as Lucentis, which, however is 40 times more expensive than the cancer fighting medicine, according to results of clinical trials published in the United States.
However, the costs of the treatments were vastly different. The average cost in the ranibizumab group per patient was $23,400 compared to $385 per patient in the bevacizumab group, the researchers said.
The study appears in the latest issue of The New England Journal of Medicine.
See the entire story at: Avastin helps fight macular degeneration: study